Suggestions
Scott Xiao
Healthcare x Technology Founder | MIT TR35
Professional Background
Scott Xiao is a pioneering figure in the realm of digital health, recognized for his creativity and innovation as a founder and leader in various tech-based health initiatives. With a rich background that blends his expertise in neuroscience and digital technology, Scott has made significant strides in healthcare, particularly in treating neuro-visual disorders. Currently, he is at the forefront of revolutionizing treatment for amblyopia (commonly known as lazy eye) through the innovative company he founded, Luminopia. This groundbreaking endeavor employs virtual reality technology to transform how healthcare is delivered to children suffering from vision loss, steering away from traditional methods like eye patches towards interactive and engaging solutions.
Scott has earned accolades for his exceptional contributions to the field, including recognition as one of the MIT Technology Review’s 35 Innovators Under 35 and making the prestigious Forbes 30 Under 30 list. These honors reflect his influence and success as a young entrepreneur in the digital health landscape, setting a standard for innovation and excellence.
Education and Achievements
Scott's journey began at Harvard University, where he studied Neuroscience, laying the foundation for his deep understanding of both the mental and physical processes related to health. This education provided him with invaluable insights that he has since translated into real-world applications. His academic background, combined with his passion for technology and health, has propelled his career forward, enabling him to engage with significant organizations and projects.
Throughout his career, Scott has held several prominent positions that showcase his leadership and expertise. He expertly led initiatives at Health Evolution as a Fellow, where he delved into the intersection of health and technology, further refining his vision for the future of healthcare. As a Co-Founder and Chief Scientific Officer at Luminopia, he has driven the development of therapies that challenge conventional methods, with clinical trials showing promising results in safety and efficacy across nearly 200 patients.
Notable Achievements
Luminopia is recognized as a trailblazer in the healthcare industry, having received the first-ever FDA approval for a VR-based therapeutic solution. This monumental milestone underlines the company’s commitment to innovation and the potential for virtual reality to enhance health outcomes in neuro-visual disorders. The company’s approach not only addresses a critical health issue affecting children but also redefines engagement with technology, making therapy more appealing and effective.
In addition to his role at Luminopia, Scott has contributed significantly as a Board Advisor at the Harvard Project for Asian and International Relations (HPAIR), fostering discussions around health and technology policy and development. His role as a Co-Founder at Odin further illustrates his entrepreneurial spirit, as he strives to harness scientific research and technological advancements for transformative health solutions.
Scott also has a history of supporting educational initiatives as the Head Mentor at the Canadian Chemistry Olympiad, where he has guided aspiring scientists and nurtured a new generation of leaders in the field. His research tenure at the Broad Institute provided him the research experience and analytical skills necessary for his later entrepreneurial endeavors.
Scott Xiao’s journey is a masterclass in leveraging education, experience, and passion to create impactful health solutions. His career is marked by a commitment to innovation, excellence, and a deeper understanding of health-related challenges, positioning him as a leading figure in the digital health sector.